The supply side of the COVID-19 vaccine rollout has garnered most of the attention. But a recent survey on American beliefs about the vaccines suggests that the bigger problem may be on the demand side of the equation.
The supply side of the COVID-19 vaccine rollout has garnered most of the attention. But a recent survey on American beliefs about the vaccines suggests that the bigger problem may be on the demand side of the equation.
After the pool of “enthusiastic” adults is vaccinated, vaccination rates are likely to start to plateau starting this month, according to Surgo Ventures, a behavioral science and artificial intelligence company. Because of holdouts, only about 52% of Americans will be vaccinated by July, according to Surgo’s projections — well short of the estimated 70% to 90% needed to achieve herd immunity.
The projection is based on the company’s analysis of results of a survey it conducted in March. Based on the respondents’ answers, Surgo groups them into five psychobehavioral categories: enthusiasts, watchful, cost-anxious, system distrusters and conspiracy believers. Surgo’s survey shows the proportion of respondents in the watchful and cost-anxious groups is shrinking compared with an earlier survey, but the proportion of system distrusters (7%) and conspiracy believers (16%) is about the same.
Surgo classifies system distrusters as being persuadable but says some of the conspiracy believers will need to get vaccinated if the U.S. population is to reach herd immunity. The company’s suggestions include tapping trusted figures to communicate risk-benefit ratios of vaccination and giving employees paid time off to get vaccinated.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More